Lisa A Kaltenbach
Overview
Explore the profile of Lisa A Kaltenbach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
953
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yonis H, Kaltenbach L, Nouhravesh N, Mark D, Blewer A, Hansen C, et al.
Resusc Plus
. 2025 Mar;
22:100897.
PMID: 40034874
No abstract available.
2.
Nelson A, Kaltenbach L, McGuire D, Levya M, Al-Khalidi H, Webb L, et al.
Am Heart J
. 2024 Dec;
282:51-57.
PMID: 39716628
Background: SGLT-2i and GLP-1RA are recommended for persons with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD); for those prescribed, little is known about reasons for discontinuation. Methods: From the...
3.
Shoji S, Kaltenbach L, Granger B, Fonarow G, Al-Khalidi H, Albert N, et al.
J Card Fail
. 2024 Apr;
30(11):1403-1410.
PMID: 38599459
Background: Randomized controlled trials typically require study-specific visits, which can burden participants and sites. Remote follow-up, such as centralized call centers for participant-reported or site-reported, holds promise for reducing costs...
4.
Diamond J, Kaltenbach L, Granger B, Fonarow G, Al-Khalidi H, Albert N, et al.
Circ Heart Fail
. 2024 Jan;
17(2):e011140.
PMID: 38205653
No abstract available.
5.
Sandhu A, Kaltenbach L, Chiswell K, Shimoga V, Ashur C, Pribish A, et al.
Circ Cardiovasc Qual Outcomes
. 2023 Nov;
16(12):e010062.
PMID: 37929603
Background: Among patients hospitalized for atrial fibrillation, the frequency of off-label direct oral anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and temporal trends in contemporary practice are unknown. Methods: Using...
6.
Rymer J, Wegermann Z, Kaltenbach L, Webb L, Peterson E, Wang T
J Am Heart Assoc
. 2023 Jun;
12(12):e029063.
PMID: 37301758
Background Premature discontinuation of P2Y12 inhibitor therapy has been associated with adverse cardiac events, which might be preventable by improving medication persistence. Current risk models have limited ability to predict...
7.
Pagidipati N, Nelson A, Kaltenbach L, Leyva M, McGuire D, Pop-Busui R, et al.
JAMA
. 2023 Mar;
329(15):1261-1270.
PMID: 36877177
Importance: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. Objective: To assess the effect of a coordinated, multifaceted intervention...
8.
Essien U, Chiswell K, Kaltenbach L, Wang T, Fonarow G, Thomas K, et al.
JAMA Cardiol
. 2022 Oct;
7(12):1207-1217.
PMID: 36287545
Importance: Oral anticoagulation (OAC) is underprescribed in underrepresented racial and ethnic group individuals with atrial fibrillation (AF). Little is known of how differential OAC prescribing relates to inequities in AF...
9.
Nelson A, Pagidipati N, Kelsey M, Ardissino M, Aroda V, Cavender M, et al.
Am Heart J
. 2022 Oct;
256:2-12.
PMID: 36279931
Several medications that are proven to reduce cardiovascular events exist for individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, however they are substantially underused in clinical practice....
10.
Rymer J, Kaltenbach L, Peterson E, Cohen D, Fonarow G, Choudhry N, et al.
J Am Heart Assoc
. 2022 Oct;
11(20):e026421.
PMID: 36250667
Background Persistence to P2Y12 inhibitors after myocardial infarction (MI) remains low. Out-of-pocket cost is cited as a factor affecting medication compliance. We examined whether a copayment intervention affected 1-year persistence...